BACKGROUND AND OBJECTIVES: Bacteraemia caused by Enterobacteriaceae (EB) producing extended-spectrum β-lactamase (ESBL+) has been associated with higher mortality compared with non-ESBL-producing (ESBL-) EB bacteraemia in observational studies. We conducted a systematic review and meta-analysis of these studies to assess how adjusting for confounding in multivariate analyses affects the pooled estimate, and whether multivariate analyses that include intermediates in the causal pathway of outcome (sepsis severity and inadequate empirical therapy) have lower estimates of attributable mortality. DATA SOURCES: PubMed search on 23 November 2010 followed by manually searching reference lists of included studies. STUDY ELIGIBILITY CRITERIA: Cohort studies published in English with separate mortality rates for ESBL+ and ESBL- EB bacteraemia. SYNTHESIS METHODS: Random-effects pooling of unadjusted and adjusted ORs followed by subgroup analyses to explore effects of adjustment procedures on adjusted ORs. RESULTS: The pooled OR for the unadjusted mortality associated with ESBL production was 2.35 (95% CI 1.90-2.91, I(2) = 42%, 32 studies). The pooled adjusted OR was 1.52 (95% CI 1.15-2.01, I(2) = 32%, 15 studies). Adjustment for more intermediates was associated with decreasing ORs. The pooled OR for the analyses adjusting for inadequate empirical therapy was 1.37 (95% CI 1.04-1.82). CONCLUSIONS: ESBL production in EB bacteraemia is associated with a higher mortality compared with bacteraemia with ESBL- EB, although the estimate of this association is affected by adjustment procedures. Adjustment for inadequate empirical therapy leads to a reduction in ORs, indicating that higher mortality is likely to be mediated through this phenomenon.
BACKGROUND AND OBJECTIVES:Bacteraemia caused by Enterobacteriaceae (EB) producing extended-spectrum β-lactamase (ESBL+) has been associated with higher mortality compared with non-ESBL-producing (ESBL-) EB bacteraemia in observational studies. We conducted a systematic review and meta-analysis of these studies to assess how adjusting for confounding in multivariate analyses affects the pooled estimate, and whether multivariate analyses that include intermediates in the causal pathway of outcome (sepsis severity and inadequate empirical therapy) have lower estimates of attributable mortality. DATA SOURCES: PubMed search on 23 November 2010 followed by manually searching reference lists of included studies. STUDY ELIGIBILITY CRITERIA: Cohort studies published in English with separate mortality rates for ESBL+ and ESBL- EB bacteraemia. SYNTHESIS METHODS: Random-effects pooling of unadjusted and adjusted ORs followed by subgroup analyses to explore effects of adjustment procedures on adjusted ORs. RESULTS: The pooled OR for the unadjusted mortality associated with ESBL production was 2.35 (95% CI 1.90-2.91, I(2) = 42%, 32 studies). The pooled adjusted OR was 1.52 (95% CI 1.15-2.01, I(2) = 32%, 15 studies). Adjustment for more intermediates was associated with decreasing ORs. The pooled OR for the analyses adjusting for inadequate empirical therapy was 1.37 (95% CI 1.04-1.82). CONCLUSIONS: ESBL production in EB bacteraemia is associated with a higher mortality compared with bacteraemia with ESBL- EB, although the estimate of this association is affected by adjustment procedures. Adjustment for inadequate empirical therapy leads to a reduction in ORs, indicating that higher mortality is likely to be mediated through this phenomenon.
Authors: Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo Journal: Clin Microbiol Rev Date: 2016-01 Impact factor: 26.132
Authors: M F Q Kluytmans-van den Bergh; C Verhulst; L E Willemsen; E Verkade; M J M Bonten; J A J W Kluytmans Journal: J Clin Microbiol Date: 2015-05-20 Impact factor: 5.948
Authors: J-H Ko; N R Lee; E-J Joo; S-Y Moon; J-K Choi; D A Park; K R Peck Journal: Eur J Clin Microbiol Infect Dis Date: 2017-11-25 Impact factor: 3.267
Authors: Zaira Raquel Palacios-Baena; Belén Gutiérrez-Gutiérrez; Marina De Cueto; Pierluigi Viale; Mario Venditti; Alicia Hernández-Torres; Antonio Oliver; Luis Martínez-Martínez; Esther Calbo; Vicente Pintado; Oriol Gasch; Benito Almirante; José Antonio Lepe; Johann Pitout; Murat Akova; Carmen Peña-Miralles; Mitchell J Schwaber; Mario Tumbarello; Evelina Tacconelli; Julia Origüen; Nuria Prim; German Bou; Helen Giamarellou; Joaquín Bermejo; Axel Hamprecht; Federico Pérez; Manuel Almela; Warren Lowman; Po-Ren Hsueh; Carolina Navarro-San Francisco; Julián Torre-Cisneros; Yehuda Carmeli; Robert A Bonomo; David L Paterson; Álvaro Pascual; Jesús Rodríguez-Baño Journal: J Antimicrob Chemother Date: 2017-03-01 Impact factor: 5.790
Authors: Marjolein F Q Kluytmans-van den Bergh; John W A Rossen; Patricia C J Bruijning-Verhagen; Marc J M Bonten; Alexander W Friedrich; Christina M J E Vandenbroucke-Grauls; Rob J L Willems; Jan A J W Kluytmans Journal: J Clin Microbiol Date: 2016-09-14 Impact factor: 5.948
Authors: Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten Journal: Antimicrob Agents Chemother Date: 2013-04-22 Impact factor: 5.191